Dr. Al-Kali on FDA Approval of Enasidenib in AML

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

Aref Al-Kali, MD, hematologist, oncologist, Mayo Clinic, discusses the FDA approval of enasidenib as a treatment for patients with relapsed or refractory IDH2-mutated acute myeloid leukemia (AML).

Related Content:

Mayo ClinicOncLive TVHematologic Oncology
Dr Kalinsky on the Future of Treatment With T-DXd in HER2+ Breast Cancer
Dr Montero on Potential Advantages With STX-478 in PI3Kα-Mutant Solid Tumors
Dr Haggstrom on Future Research Directions in EGFR+ and ALK+ NSCLC